| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Harrington Robert Arthur serves as a Director at CYTK. Across recent SEC filings that breaks down to 0 buys and 6 sells. Those positions are worth an estimated $1.4M at current prices.
Historically, Harrington Robert Arthur's trades have earned a middling insider score of 51/100 across 6 rated trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of -7.9%.
The biggest single holding is CYTK (~$1.4M) as Director. The recent filings there lean toward selling, a net 7,483 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 1, 2025 | CYTK Cytokinetics Inc | Director | Sell | 2,150 | $66.80 | $143,620.00 | -10.4% | -6.9% | - | |
| Sep 2, 2025 | CYTK Cytokinetics Inc | Director | Sell | 2,150 | $48.67 | $104,640.50 | -9.5% | +33.1% | - | |
| Apr 3, 2025 | CYTK Cytokinetics Inc | Director | Sell | 450 | $39.43 | $17,743.50 | -3.0% | -15.2% | +64.7% | |
| Mar 4, 2025 | CYTK Cytokinetics Inc | Director | Sell | 900 | $42.50 | $38,250.00 | -5.6% | -28.6% | +42.5% | |
| Jul 5, 2024 | CYTK Cytokinetics Inc | Director | Sell | 253 | $54.61 | $13,816.33 | -1.6% | +0.4% | -39.9% | |
| Jun 3, 2024 | CYTK Cytokinetics Inc | Director | Sell | 1,580 | $48.64 | $76,851.20 | -9.2% | +9.4% | -35.8% |